{'fraction_non_alphanumeric': 0.016018306636155607, 'fraction_numerical': 0.018306636155606407, 'mean_word_length': 4.615384615384615, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A phase II study of alanosine in advanced large bowel carcinoma

Thirty patients with advanced metastatic colo-rectal adenocarcinoma were treated with alanosine at a dose of 160 mg/m2 daily for 5 days every 4 weeks. Sixteen patients had received no prior chemotherapy and 14 had been previously treated with one or more cyto-toxic agents. No patient met the criteria for a complete or partial response. The major toxicity was stomatitis.